These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23169326)

  • 1. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.
    Clouse K; Pettifor A; Maskew M; Bassett J; Van Rie A; Gay C; Behets F; Sanne I; Fox MP
    AIDS; 2013 Feb; 27(4):645-50. PubMed ID: 23169326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
    Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
    AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.
    Grimsrud A; Cornell M; Schomaker M; Fox MP; Orrell C; Prozesky H; Stinson K; Tanser F; Egger M; Myer L;
    J Epidemiol Community Health; 2016 Jun; 70(6):549-55. PubMed ID: 26700300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
    Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
    J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study.
    Dorward J; Sookrajh Y; Gate K; Khubone T; Mtshaka N; Mlisana K; Ngobese H; Yende-Zuma N; Garrett N
    J Int AIDS Soc; 2020 Apr; 23(4):e25479. PubMed ID: 32319203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.
    Bock P; Fatti G; Ford N; Jennings K; Kruger J; Gunst C; Louis F; Grobbelaar N; Shanaube K; Floyd S; Grimwood A; Hayes R; Ayles H; Fidler S; Beyers N;
    PLoS One; 2018; 13(4):e0195127. PubMed ID: 29672542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
    Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
    PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.
    Brennan AT; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2013 May; 18(5):619-31. PubMed ID: 23419157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.
    Onoya D; Sineke T; Brennan AT; Long L; Fox MP
    AIDS; 2017 Jul; 31(11):1593-1602. PubMed ID: 28463877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vitamin D
    Sudfeld CR; Mugusi F; Aboud S; Nagu TJ; Wang M; Fawzi WW
    Trials; 2017 Feb; 18(1):66. PubMed ID: 28183335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.
    Deconinck L; Yazdanpanah Y; Gilson RJ; Melliez H; Viget N; Joly V; Sabin CA
    HIV Med; 2015 Apr; 16(4):219-29. PubMed ID: 25522796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
    AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008-2011.
    Allam RR; Murhekar MV; Bhatnagar T; Uthappa CK; Nalini C; Rewari BB; Mehendale SM
    Trans R Soc Trop Med Hyg; 2015 May; 109(5):325-33. PubMed ID: 25778736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.
    Nash D; Wu Y; Elul B; Hoos D; El Sadr W;
    AIDS; 2011 Jul; 25(12):1523-33. PubMed ID: 21750418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.
    Alvarez-Uria G; Naik PK; Pakam R; Midde M
    Glob Health Action; 2013 Sep; 6():21682. PubMed ID: 24028937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
    Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
    Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The social and clinical characteristics of patients on antiretroviral therapy who are 'lost to follow-up' in KwaZulu-Natal, South Africa: a prospective study.
    Peltzer K; Ramlagan S; Khan MS; Gaede B
    SAHARA J; 2011; 8(4):179-86. PubMed ID: 23236959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.